AzTrials
AzTrials

Acute Leukemia, High RiskPhase 1/2ECT-001-CB-013NCT07301866

A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

A Phase 1/2 study testing ECT-001-CB in people with Acute Leukemia, High Risk and Myelodysplastic Syndromes, High Risk, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Read more about this study

Who is it for?
Ages 18 to 67 years
What is being tested?
ECT-001-CB
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
1 siteCanada
Study dates
6 Oct 2025to Mar 2028
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 67 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects ≥ 18 and ≤ 67 years old,
  • Patient with either i. High risk acute leukemia or myelodysplasia defined as expected 2 year OS or PFS < 40% after a conventional allogeneic HSC transplant or ii. A hematologic malignancy requiring an allogeneic hematopoietic stem cell transplant and lack of a suitable HLA identical, haploidentical or 7/8 HLA matched donor.
  • Availability of an adequate CB for expansion:
  • ≥ 5/8 HLA match when A, B, C and DRB1 are performed at the allele level.
  • Minimal cell dose: TNC ≥ 1.5 x 107/kg, and CD34 ≥ 0.5 x 105/kg. iii. Needs to be erythrodepleted by bank prior to cryopreservation. iv. Must comply with local site regulations AND, come from a cord bank that is FACT, or AABB accredited, or FDA approved or eligible for NMDP IND (unless PI approves another bank).
  • To meet eligibility criteria, the patient's weight at time of cord selection will be used; however, if this weight has increased by more than 5% at time of admission to hospital and with the new weight the patient no longer meets eligibility criteria for cell dose, LI approval will be required to move forward with the selected cord. Every attempt will be made to always use the most recent weight in cord selection
Show all 14Show fewer
  • Patients with adequate physical function as measured by:
  • Karnofsky score ≥ 70% ii. Hematopoietic comorbidity index (HCT-CI): 0-3 for 2nd transplant and age 60-65 years, 0-5 if <60 years old, and 0-2 if 66-67 years.
  • Adequate cardiac function: Left ventricular ejection fraction ≥ 40% within 60 days prior to start of conditioning regimen iv. Adequate pulmonary function: Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted within 60 days prior to start of conditioning regimen.
  • Adequate hepatic function: Bilirubin < 2 x ULN unless felt to be related to Gilbert's disease or hemolysis; AST and ALT ≤ 2.5 x ULN (the PI may approve up to 3 times ULN) ; alkaline phosphatase ≤ 5 x ULN.
  • Adequate renal function: Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2.
  • A back up graft must have been identified prior to initiation of conditioning regimen.
  • Signed written informed consent.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 30 days of enrolment and within 30 days of starting of preparative regimen; patient must be willing to use an effective contraceptive method while enrolled in the study.

Who cannot join

  • Allogeneic or autologous myeloablative transplant within last 6 months.
  • Patients with inadequate physical function as measured by:
  • Active, uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of either progression of clinical symptoms or radiologic findings or lack of evidence of response to therapy).
  • Presence of a malignancy other than the one for which the HSC transplant is being performed, with an expected survival estimated to be less than 75% at 5 years.
  • Seropositivity for HIV. iv. Hepatitis B or C infection with measurable viral load. Patients with hepatitis B or C infection regardless of viral load require clear documentation of absence of cirrhosis by either fibroscan or biopsy.
  • Liver cirrhosis.
Show all 10Show fewer
  • Positive anti-donor HLA antibodies with MFI above 1500 against the selected CB (PI may approve an MFI up to 5000; if above 2500, desensitization is strongly recommended)
  • Use of an investigational agent within 30 days (defined as a drug not approved by Health Canada or FDA regardless of indication) of start of chemotherapy unless documented approval obtained from Sponsor.
  • Presence of ≥30% blasts in bone marrow or ≥ 0.5 x109/L blasts in circulating blood
  • Active central nervous system involvement or chloroma > 2 cm.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sandra Cohen, Dr. contact

514-252-3404

sandra.cohen.med@ssss.gouv.qc.ca

Canada1 site, 1 recruiting

  • Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4

    Sandra Cohen, Dr., 514-252-3404, sandra.cohen.med@ssss.gouv.qc.ca

    Recruiting

Other trials in Canada

About this study

Official title: Single-site, Prospective, Open-label Phase I-II Study on Transplantation Using Cord Blood Treated With an Optimized Dose of UM171: Optimized ECT-001-CB.

This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications.

In this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hypothesis is that using a higher dose of UM171 to expand cord blood stem cells will help patients recover blood counts faster after transplant by improving the growth and function of the cells. This may lead to better immune recovery, fewer infections, shorter hospital stays, and improved overall outcomes.

Only seven patients will be enrolled, and they will be followed for one year after their transplant.

Read the detailed description

This is a single-center, prospective, open-label, dose-escalating Phase I/II clinical trial designed to evaluate the safety, feasibility, and efficacy of ECT-001-CB cord blood transplantation using an optimized dose of UM171, a small molecule that enhances hematopoietic stem cell (HSC) expansion.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients with high-risk hematologic malignancies. However, some patients lack a suitable donor. Cord blood (CB) is a valuable alternative donor source due to its tolerance for HLA mismatches and lower incidence of chronic graft-versus-host disease (GVHD). Despite these advantages, CB transplantation has declined due to limitations such as low cell dose, delayed engraftment, and increased non-relapse mortality (NRM).

UM171 is a proprietary molecule that has demonstrated the ability to expand CD34⁺ HSCs ex vivo, thereby addressing the cell dose limitation of CB transplants. Previous trials using UM171-expanded CB units (ECT-001-CB) showed promising results, including faster engraftment, improved immune reconstitution, and reduced NRM.

This study builds on prior findings by investigating whether a higher dose of UM171 (125nM vs. the conventional 35nM) can further accelerate neutrophil engraftment and enhance immune recovery. Preclinical data suggest that higher UM171 concentrations may increase the number of long-term repopulating HSCs and promote balanced lymphoid and myeloid differentiation, potentially improving clinical outcomes.

Seven patients with high-risk acute leukemia or myelodysplasia, or other hematologic malignancies requiring HSCT and lacking a suitable donor, will be enrolled over a 12-month period. Patients will receive a single ECT-001-CB transplant following an intermediate or high-intensity conditioning regimen. The CB unit will be expanded ex vivo with escalating doses of UM171 (starting at 70nM, potentially increasing to 125nM based on engraftment outcomes).

Primary endpoints include safety (grade ≥3 adverse events), feasibility of manufacturing and infusion, and time to neutrophil engraftment. Secondary endpoints include NRM, platelet engraftment, graft failure, progression-free survival (PFS), overall survival (OS), incidence of acute and chronic GVHD, immune reconstitution, and time to hospital discharge. Exploratory endpoints include infectious complications, relapse incidence, GVHD-free relapse-free survival (GRFS), advanced immunologic profiling, and comparisons with historical controls.

Safety will be monitored by an independent Data Safety Monitoring Board (DSMB). The study includes predefined stopping rules to ensure patient safety, including thresholds for engraftment delay, graft failure, NRM, and severe GVHD.

This trial aims to optimize CB transplantation by enhancing the efficacy of UM171-expanded grafts, potentially offering a safer and more effective treatment option for patients with limited donor availability.

Being tested
ECT-001-CB
Keywords
High risk hematologic malignancy, Cord blood transplant, UM171, ECT-001-CB, Lack of donor for stem cell transplant donor, Acute leukemia, Myelodysplastic syndrome
Medical subject headings
Myelodysplastic Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ECT-001-CBBiological

    UM171-expanded cord blood

Study groups in NCT07301866
Study groupRoleWhat they receive
UM171 CB transplant (ECT-001-CB) with optimized dose of UM171ExperimentalNot described
Receives: Biological: ECT-001-CB

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of grade 3 or higher adverse events (AEs)

    Incidence of grade 3 or higher adverse events (AEs)

    Measured: From the start of pre-transplant conditioning of first patient throught 1 year post-transplant of last patient

  2. Feasibility of manufacturing and infusion

    Proportion of selected grafts that will be expanded and meet release criteria and be successfully infused to the patient

    Measured: From first day of product manufacturing for the first patient throught the infusion of the product to the last patient, up to Month 13.

  3. Time to neutrophil engraftment

    Neutrophil engraftment is defined as the first day of neutrophil count (ANC) ≥ 0.5 x 109/L for 3 consecutive days; first day of ANC ≥ 0.1 x 109/L will also be documented.

    Measured: From day of transplant (Day 0) throught day of neutrophil engraftment, up to Day 42 post-transplant.

Secondary outcomes (8)

  1. Incidence of NRM at 1 year post transplant

    Defined as death not preceded by recurrent or progressive malignancy occurring anytime after stem cell infusion

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  2. Time to platelet engraftment

    Platelet engraftment is defined as the first of 3 days of a sustained platelet count ≥ 20 x 109/L with no platelet transfusion in the preceding 7 days as per CIBMTR standards.

    Measured: From day of transplant (Day 0) throught day of platelet engraftment, up to Day 42 post-transplant.

  3. Incidence of graft failure

    The incidence of graft failure will be monitored throughout the protocol until 1 year post transplant

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  4. Progression-free survival (PFS) at 1 year post-transplant

    Relapse/progression is defined by either hematologic or extramedullary evidence of disease.

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  5. Overall Survival (OS) at 1 year post-transplant

    OS is defined as the time interval between day of transplant until death from any cause or for surviving patients, to last follow-up. An event is defined as death from any cause

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  6. Incidences of grade 2-4, 3-4 acute and moderate-severe chronic GVHD at 1 year

    Standard clinical criteria and histologic evaluation when possible of skin, liver or gastrointestinal tract will be used to establish and grade acute GVHD. The time to onset of acute GVHD grade 2-4 and maximal grade will be recorded. More specifically, time of onset to grade 2 GVHD as well as time of onset of grade 3 or 4 acute GVHD will be collected.

    Cumulative incidence of moderate-severe chronic GVHD will be determined at 12 months. Chronic GVHD will be diagnosed and graded according to the recommendations of the NIH Consensus Conference and recently updated.

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  7. Immune reconstitution at 2, 3, 6 and 12 months

    CD4+, NK and B cell counts (T-B-NK panel) and IgG levels will be measured at 2, 3, 6, and 12 months post-transplant. These results may be compared to conventional dose ECT-001-CB transplants or other types of transplant.

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

  8. Time to discharge from hospital

    Duration of initial transplant hospitalization will be measured from day of transplant until day of hospital discharge. These results may be compared to various control groups

    Measured: From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study start6 Oct 2025
  3. Primary completionOct 2027 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
7 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07301866
Sponsor's protocol ID
ECT-001-CB-013
Acronym
ECT-001-CB-013
Status last verified
Dec 2025
First submitted
27 Nov 2025
Last updated
24 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Description: The sponsor plans to share IPD collected during the trial, including de-identified clinical data and biological sample results, with qualified researchers for secondary analyses. This includes data related to: Primary and secondary endpoints (e.g., neutrophil engraftment, GVHD incidence, survival outcomes) Safety data (e.g., adverse events, serious adverse events) Demographic and baseline characteristics What IPD Will Be Shared: * De-identified individual-level clinical data * Immune profiling and chimerism data * Adverse event and safety data * Outcome measures (e.g., engraftment times, relapse, survival)

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing ECT-001-CB in people with Acute Leukemia, High Risk and Myelodysplastic Syndromes, High Risk, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sandra Cohen, Dr. (514-252-3404, sandra.cohen.med@ssss.gouv.qc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of grade 3 or higher adverse events (AEs) (time frame: From the start of pre-transplant conditioning of first patient throught 1 year post-transplant of last patient). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07301866.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in